Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 iBio Advances COVID-19 Vaccine Candidate | Contract Pharma

What are you searching for?

Sign in
Breaking News

iBio Advances COVID-19 Vaccine Candidate

IBIO-201 induced the production of anti-spike neutralizing antibodies in tests.

By: Contract Pharma

Contract Pharma Staff

iBio Inc., a biotech innovator and biologics contract manufacturing organization, has selected IBIO-201, its LicKM-ubunit vaccine, as its leading candidate for the prevention of SARS-CoV-2 infection.
 
iBio previously announced that preclinical immunization studies with IBIO-200 and IBIO-201, combined with select adjuvants from the Infectious Disease Research Institute (IDRI), induced anti-SARS-CoV-2 antibodies. Additional data from cell-based pseudovirus neutralization assay testing demonstrate that IBIO-201 induced the production of more anti-spike neutralizing antibodies than IBIO-200 in immunized mice.
 
“Our decision to evaluate IBIO-200 and IBIO-201 in tandem, and in combination with multiple adjuvants, proved beneficial given the results observed with IBIO-201 in preclinical studies,” said Tom Isett, chairman & CEO of iBio. “While IBIO-201 produced significantly higher anti-spike neutralizing antibody titers than IBIO-200, we are still encouraged by the potential of IBIO-200.”
 
Isett continued, “We plan to conduct more focused studies on each of IBIO-200 and IBIO-201, with the goal of advancing IBIO-201 to toxicology studies ahead of planned clinical development. Meanwhile, we intend to continue preclinical development of IBIO-200 and our virus-like particle platform as a potential ‘plug-and-play’ vaccine development system.”
 
iBio continues to work with IDRI and the Texas A&M University System, and expects to engage additional collaborators for further characterization and testing of IBIO-201 prior to performing GLP toxicology studies.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics